

CNMV
Edison, 4
28006 Madrid

Barcelona (Spain), March 30, 2017

RELEVANT FACT

Dear Sir,

In accordance with the Article 228 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company") submits hereafter press release on the inauguration of a new development and quality control laboratory.

Adolf Rousaud
Secretary of the Board of Directors
Laboratorio Reig Jofre SA

Reinforcement of the quality control area

REIG JOFRE INAUGURATES A NEW ANALYTICAL LABORATORY FOR DEVELOPMENT AND QUALITY CONTROL IN ITS HEADQUARTERS OF SANT JOAN DESPI, BARCELONA

- The new analytical laboratory for development and quality control has an area of 1200 sq. m. equipped with state-of-the-art technology and designed for the incorporation of "rapid microbiology" techniques.
- The new facility involved an investment of 4 M€ and it will allow to increase capacity and to undertake major projects in biotechnology, as well as to address the major entry challenges of demanding markets as Japan, Korea, Brazil or USA.

Barcelona, March 30, 2017. Mr. Antoni Poveda, mayor of Sant Joan Despi (Barcelona) formally inaugurated yesterday the new analytical laboratory for development and quality control of the pharmaceutical company Reig Jofre.

The new facilities have an area of 1200 sq. m. and they will increase capacity and strengthen the areas of chromatography and microbiology with the necessary equipment to incorporate "rapid microbiology" techniques with which to shorten response times, increase efficiency and reduce costs. In addition, the facilities will allow to undertake larger scale biotech projects.

In this sense, the new facilities are expected to strengthen Reig Jofre's position as a strategic partner in the development and production of freeze-dried products for companies that need to stabilize and freeze innovative complex actives and industrialize badges for clinical research and marketing.

The new analytical laboratory complies with the fundamental guidelines established in the good manufacturing practice (GMP), which define standards of quality in the manufacture of medicines, as well as the principles of good laboratory practice (GLP) and occupational risk prevention (ORP).



Additionally, the new facilities will increase capacity and reinforce the quality controls that Reig Jofre has been implementing to meet and maintain the demanding requirements of evaluation by the major medicines agencies such as: EMA, Europe; FDA, USA; PMDA, Japan; KFDA, Korea and ANVISA, Brazil.

The investment to carry out this improvement amounted to 4 million euros and it is framed within a determined investment policy to address ongoing industrial and commercial growth projects, which includes expansion of productive capacity and larger investments in R&D.

The company's headquarters in Sant Joan Despi exceeded 330 employees in 2016, 110 of whom are assigned to the new laboratory.

Reig Jofre closed 2016 with 927 employees, after 72 new additions throughout the year, in the several company headquarters.

Internationalization is one of the strategic pillars of growth established in the company's plan and optimum quality control is essential to address the important challenges of entry into these markets.

Get timely updates of Reig Jofre news by registering in the company's **subscription centre** on the corporate website: **www.reigjofre.com**

About Reig Jofre

Founded in Barcelona in 1929, Reig Jofre is a multinational pharmaceutical company with activity structured around two major axes: the main one, own-product manufacture and marketing (RJF Pharma, 80% of total sales) and a complementary one, development and manufacture for third parties (RJF CDMO, 20% of total sales). In its main activity, the company focuses on developing specialised technological products (antibiotics and solutions for injection); specialised therapeutic products for the dermatology, gynaecology and respiratory fields; and dietary supplements and consumer healthcare. The company focuses its R+D activity on developing new indications and/or pharmaceutical forms using known active substances, generic medicines with a particular focus on beta-lactam antibiotics and solutions for injection, topical dermatological products, OTCs and dietary supplements, and in addition develops new innovative molecules in partnership with start-ups and research centres.

Reig Jofre has over 900 employees, 4 development centres and 3 production centres in Europe, direct sales in 6 European countries and over 130 business partners in 63 countries across the world. The company closed 2016 with a turnover of 161 million euros.

Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Share capital: 63,214,220 shares.



For further information:

Investors and analysts

Gloria Folch

Tel. (+34) 93 480 67 10 – ext. 1241

gloria.folch@reigjofre.com

Media

Inma Santa-Pau

Tel. (+34) 93 480 67 10 – ext. 1242

inma.santapau@reigjofre.com